Velocity Clinical Research

OCTOBER 3, 2024

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.”

Gene Therapy 52

Gene Therapy Gene Genetic Engineering Clinical Research 52

Advarra

AUGUST 10, 2023

Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. Peter Marks, head of FDA’s CBER – the organization responsible for regulating gene therapies.

Gene Therapy 52

Gene Therapy Development Gene Drugs 52

Advarra

JUNE 13, 2023

Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. The accelerating gene therapy market is expected to grow globally by 16.6% An IRB tends to get the most attention since all human trials need IRB approval.

Gene Therapy 52

Gene Therapy Gene Research Genetic Engineering 52

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

NY Times

SEPTEMBER 14, 2021

Will the Biden administration commit to spending that could speed clinical trial results? Such treatments are extraordinarily promising and costly.

Gene Therapy 93

Gene Therapy Clinical Trials Clinical Trials Gene 93

Roots Analysis

AUGUST 31, 2023

The applications of gene switch platforms can be broadly classified into the following two categories: Endogenous Gene Regulation Exogenous Gene Regulation Endogenous Gene Regulation The ability to regulate endogenous genes has various applications in biological research and gene therapy development.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

The Pharma Data

JANUARY 10, 2021

The new year began with a fairly low level of clinical trial news. Arcturus Therapeutics got the FDA go-ahead for its Phase II trial of its COVID-19 vaccine candidate ARCT-021. The trial will enroll 600 participants, with 450 receiving ARCT-021 and 150 receiving placebo. FBX-101 is a first-in-human AAV gene therapy.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Either way, occupational exposure to these gene delivery systems bears potential risks to the research staff.

Engineer 52

Engineer Genetics Clinical Research Research 52

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. WCG has many ways to support cell and gene therapy clinical trials for lupus.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

Advarra

OCTOBER 10, 2024

While developing an entirely new class of antibiotic is challenging, making minor genetic modifications to a virus or phage is something fairly easily accomplished with modern technologies. Intra-venous delivery of phages has potential as therapeutics for a broad range of conditions caused by antibiotic-resistant E.

Bacteria 52

Bacteria Genetics Genetic Engineering Gene 52

XTalks

NOVEMBER 29, 2024

The acquisition also grants Roche access to Poseida’s P-CD19CD20-ALLO1, a dual-target CAR-T therapy currently in Phase I trials for B-cell malignancies. Additionally, Poseida’s solid tumor program, P-MUC1C-ALLO1, is advancing in Phase I trials, targeting antigen-expressing tumors with promising early results.

Gene Therapy 100

Gene Therapy Gene Gene Editing Genetic Engineering 100